Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface

Kohta Yamamoto, Masafumi Makino, Ramida Watanapokasin, Etsu Tashiro, Masaya Imoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for cancer treatment. This is because of its selective cytotoxicity against various cancer cells without a detrimental effect on normal cells. However, recent studies have reported that the potential application of TRAIL in cancer therapy is limited, as many cancer cells have been found to be resistant to TRAIL. Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL. Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in HCT116 cells. Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the apoptosis that was synergistically induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin increased the expression of DR5 on the cell surface. Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced apoptosis. Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in tumor cells.

Original languageEnglish
Pages (from-to)295-300
Number of pages6
JournalJournal of Antibiotics
Volume65
Issue number6
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

Up-Regulation
Apoptosis
Neoplasms
HCT116 Cells
Caspases
inostamycin
Therapeutics
Tumor Necrosis Factor-alpha
Ligands

Keywords

  • apoptosis
  • DR5
  • inostamycin
  • TRAIL

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface. / Yamamoto, Kohta; Makino, Masafumi; Watanapokasin, Ramida; Tashiro, Etsu; Imoto, Masaya.

In: Journal of Antibiotics, Vol. 65, No. 6, 06.2012, p. 295-300.

Research output: Contribution to journalArticle

Yamamoto, Kohta ; Makino, Masafumi ; Watanapokasin, Ramida ; Tashiro, Etsu ; Imoto, Masaya. / Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface. In: Journal of Antibiotics. 2012 ; Vol. 65, No. 6. pp. 295-300.
@article{b12df426219a44cbab69da0a32c9ab36,
title = "Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for cancer treatment. This is because of its selective cytotoxicity against various cancer cells without a detrimental effect on normal cells. However, recent studies have reported that the potential application of TRAIL in cancer therapy is limited, as many cancer cells have been found to be resistant to TRAIL. Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL. Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in HCT116 cells. Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the apoptosis that was synergistically induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin increased the expression of DR5 on the cell surface. Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced apoptosis. Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in tumor cells.",
keywords = "apoptosis, DR5, inostamycin, TRAIL",
author = "Kohta Yamamoto and Masafumi Makino and Ramida Watanapokasin and Etsu Tashiro and Masaya Imoto",
year = "2012",
month = "6",
doi = "10.1038/ja.2012.21",
language = "English",
volume = "65",
pages = "295--300",
journal = "Journal of Antibiotics",
issn = "0021-8820",
publisher = "Japan Antibiotics Research Association",
number = "6",

}

TY - JOUR

T1 - Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface

AU - Yamamoto, Kohta

AU - Makino, Masafumi

AU - Watanapokasin, Ramida

AU - Tashiro, Etsu

AU - Imoto, Masaya

PY - 2012/6

Y1 - 2012/6

N2 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for cancer treatment. This is because of its selective cytotoxicity against various cancer cells without a detrimental effect on normal cells. However, recent studies have reported that the potential application of TRAIL in cancer therapy is limited, as many cancer cells have been found to be resistant to TRAIL. Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL. Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in HCT116 cells. Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the apoptosis that was synergistically induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin increased the expression of DR5 on the cell surface. Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced apoptosis. Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in tumor cells.

AB - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered as a possible therapeutic agent for cancer treatment. This is because of its selective cytotoxicity against various cancer cells without a detrimental effect on normal cells. However, recent studies have reported that the potential application of TRAIL in cancer therapy is limited, as many cancer cells have been found to be resistant to TRAIL. Therefore, small molecule compounds that potentiate the cytotoxicity of TRAIL would be strategic candidates for therapeutic applications in combination with TRAIL. Here we found that a combined treatment of inostamycin and TRAIL synergistically induced caspase-dependent apoptosis in HCT116 cells. Inostamycin upregulated DR5, and a knockdown of DR5 suppressed the apoptosis that was synergistically induced by co-treatment with inostamycin and TRAIL. Moreover, inostamycin increased the expression of DR5 on the cell surface. Therefore, inostamycin-increased cell surface expression of DR5 may have contributed to the enhancement of TRAIL-induced apoptosis. Our study suggests that combined treatment with inostamycin and TRAIL may offer a strategy to overcome TRAIL resistance in tumor cells.

KW - apoptosis

KW - DR5

KW - inostamycin

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=84863332135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863332135&partnerID=8YFLogxK

U2 - 10.1038/ja.2012.21

DO - 10.1038/ja.2012.21

M3 - Article

C2 - 22472572

AN - SCOPUS:84863332135

VL - 65

SP - 295

EP - 300

JO - Journal of Antibiotics

JF - Journal of Antibiotics

SN - 0021-8820

IS - 6

ER -